Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

HPV screening: Primary human papilloma virus DNA screening with Qiagen/Digene's Hybrid Capture 2 followed by cytology triage is more sensitive in detecting cervical lesions than conventional cytology screening, according to a large-scale Finnish study published in the Dec. 2 issue of the Journal of the National Cancer Institute. In women 35 or older, the method also showed greater specificity and decreased colposcopy referrals and follow-up tests. An accompanying editorial by Eduardo L. Franco, McGill University, notes that as more young women who have received the HPV vaccine reach screening age, "the reduced prevalence of abnormalities may adversely affect the performance of cytology if it is left as the sole screening test.

You may also be interested in...

Qiagen's HC2 More Effective Than Pap Test In Preventing Cancer - Study

Qiagen/Digene's Hybrid Capture 2 human papillomavirus (HPV) DNA test is more effective than Pap testing alone in preventing cervical cancer, according to the results of a large-scale study published online Jan. 19 in The Lancet Oncology

Belgium Aims To Drive Biologic Competition Through Tendering

New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts